TFF Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants
FORT WORTH, Texas, Nov. 17, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on...
Pharmaceutical
MiNK Therapeutics to Participate in Evercore ISI HealthCONx Conference
NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization...
Rakovina Therapeutics Inc. Announces Q3 2022 Financial Results and Provides Corporate Update
VANCOUVER, British Columbia, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed...
RespireRx Pharmaceuticals Inc. Announces Entry into Letter of Intent with Australian Headquartered CRO for Dronabinol Development for Obstructive Sleep Apnea
Glen Rock, N.J., Nov. 17, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market:RSPI) (“RespireRx” or the “Company”), a...
ABVC BioPharma Provides Vitargus® Update – Phase II Vitargus® Study Protocol Received Thai FDA Approval
FREMONT, CA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical...
Palisade Bio Releases In-Depth Explanation of Scientific Approach of Lead Product Candidate LB1148 Through Animated Video
Video illustrates the potential of LB1148 to reduce the formation of adhesions in gastrointestinal (GI) tissues and accelerate the time...
Mesa Labs Acquires Belyntic’s Peptide Purification Business
Lakewood, Colorado, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“we”, “Mesa” or the “Company”), a global leader...
VYNE Therapeutics Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo
Topline proof-of-concept data in vitiligo patients expected in 1H 2023BRIDGEWATER, N.J., Nov. 17, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc....
Ayala Pharmaceuticals Presents Poster on AL102 in Desmoid Tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting
REHOVOT, Israel and WILMINGTON, Del., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company...
Longitude Capital Expands Biotechnology Practice With Matthew Young, Former Grail COO and Jazz EVP, and Cadre of New Talent
- Young held senior leadership positions at GRAIL and Jazz Pharmaceuticals after successful 20-year investment banking career at Barclays, Citigroup,...
Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research
Phase 1 results showed that AV-101 was generally well tolerated with significantly reduced systemic exposure compared to oral imatinib in...
Life sciences executive Dr Georgia Papathomas joins Indegene’s Board as Independent Director
PRINCETON, N.J. and BANGALORE, India, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, today announced...
InMed Provides Update on Management Changes
VANCOUVER, British Columbia, Nov. 17, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader...
Day One to Participate in the Piper Sandler 34th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated...
Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders
SAN FRANCISCO and PHILADELPHIA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines...
Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19
-Broad partnership will strengthen Invivyd’s development platform and organizational capabilities towards acceleration of NVD200 clinical program and future engineered antibodies...
FundaMental Pharma launches with EUR 10 million in Seed financing led by BGV and Thuja Capital to advance a First-in-Class neuroprotectant
PRESS RELEASE FundaMental Pharma launches with EUR 10 million in Seed financing led by BGV and Thuja Capital to advance...
Immatics Announces Third Quarter 2022 Financial Results and Business Update
Interim clinical update on ACTengine® IMA203 TCR-T monotherapy targeting PRAME demonstrated high confirmed objective response rate (cORR) of 50% (6/12)...
CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
- Collaboration will enable the development of investigational next-generation bispecific immunotherapies using CytomX’s Probody® and Regeneron's Veloci-Bi® platforms - -...
atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment
NEW YORK and BERLIN, Nov. 17, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical...